登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600420 证券简称：国药现代 公告编号：2025-042 上海现代制药股份有限公司 剂型：片剂（薄膜衣） 规格：0.25g 注册分类：化学药品 关于药品通过仿制药一致性评价的 自愿性信息披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 近日，上海现代制药股份有限公司（以下简称公司）及全资子公司国药集团容生制药有限公司（以下简 称国药容生）分别收到国家药品监督管理局核准签发的《药品补充申请批准通知书》。现将相关情况公 告如下： 一、阿奇霉素片 （一）药品基本信息 药品名称：阿奇霉素片 通知书编号：2025B02440 原药品批准文号：国药准字H20000477 上市许可持有人：上海现代制药股份有限公司 药品生产企业：上海现代制药股份有限公司 审批结论：根据《中华人民共和国药品管理法》、《国务院关于改革药品医疗器械审评审批制度的意 见》（国发〔2015〕44号）和《关于仿制药质量和疗效一致性评价工作有关事项的公告》（2017年第 100号）规定，经审查，本品通 ...

Core Viewpoint - The company and its wholly-owned subsidiary have received approval for two generic drugs, which is expected to enhance market expansion and sales opportunities [1] Group 1: Drug Approvals - The company received the "Drug Supplement Application Approval Notice" from the National Medical Products Administration for Azithromycin Tablets and Dihydrocodeine Injection [1] - Both drugs have passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 2: Market Potential - Azithromycin Tablets are indicated for infections caused by sensitive bacteria, with projected sales of 685 million yuan in public medical institutions and urban pharmacies in 2024 [1] - Dihydrocodeine Injection is used for treating bronchial asthma, with expected sales of 135 million yuan in public medical institutions in 2024 [1] - The successful evaluation is beneficial for product market expansion and sales [1]